These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 4127178)

  • 21. Lactate dehydrogenase isoenzymes in human prostatic fluid: an aid in recognition of malignancy?
    Grayhack JT; Wendel EF; Lee C; Oliver L; Cohen E
    J Urol; 1977 Jul; 118(1 Pt 2):204-8. PubMed ID: 69042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostatic hexosaminidase activity in patients with benign prostatic hyperplasia and prostatic carcinoma.
    Whitehurst GB; Mashburn JP; Pretlow TG; Bradley EL; Boohaker EA
    Cancer Res; 1982 Oct; 42(10):4300-3. PubMed ID: 6179600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [LDH index in the diagnosis of prostatic diseases].
    Lalanne MG; De Santis P; Mazzuca A
    Minerva Urol; 1983; 35(4):243-5. PubMed ID: 6201706
    [No Abstract]   [Full Text] [Related]  

  • 24. Benign mimics of prostatic adenocarcinoma on needle biopsy.
    Gaudin PB; Reuter VE
    Anat Pathol; 1997; 2():111-34. PubMed ID: 9575372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzyme studies in human prostatic tissues.
    Deshpande N; Mitchell I; Towler J
    Clin Oncol; 1983 Mar; 9(1):25-30. PubMed ID: 6189658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment].
    Pushkar' DIu; Rasner PI; Skobelev PP
    Urologiia; 2001; (6):48-54. PubMed ID: 11785083
    [No Abstract]   [Full Text] [Related]  

  • 27. Lactate dehydrogenase isoenzymes in hyperplasia and carcinoma of the prostate: a clinical study.
    Elhilali MM; Oliver JA; Sherwin AL; Mackinnon KJ
    J Urol; 1967 Dec; 98(6):686-92. PubMed ID: 4169732
    [No Abstract]   [Full Text] [Related]  

  • 28. The histochemical behaviour, electrophoretic mobility and distribution in cell fractions of acid phosphatase isozymes in prostatic cancer and benign prostate hyperplasia.
    Fischer DR; Gevers W; Klerk JN; Kühn S
    Int Urol Nephrol; 1979; 11(2):111-8. PubMed ID: 89105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of fine needle aspiration cytology (FNAC) in the diagnosis of prostatic lesions with histologic correlation.
    Saleh AF; Nahar Rahman AJ; Salam MA; Islam F
    Bangladesh Med Res Counc Bull; 2005 Dec; 31(3):95-103. PubMed ID: 17549870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Diagnosis and therapy of prostatic carcinoma].
    Vahlensieck W; Tümmers H; Tschischak D
    Fortschr Med; 1974 Oct; 92(30):1195-8. PubMed ID: 4138473
    [No Abstract]   [Full Text] [Related]  

  • 31. Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications.
    Wang K; Fan DD; Jin S; Xing NZ; Niu YN
    Asian J Androl; 2014; 16(2):274-9. PubMed ID: 24457841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
    Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
    Urologiia; 2001; (2):37-40. PubMed ID: 11490716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leucine-arylamidase activity in untreated and treated benign prostatic hypertrophy and adenocarcinomatous prostate.
    Verlooy J; van Sande M; Van Camp K
    Acta Urol Belg; 1981 Oct; 49(4):491-5. PubMed ID: 6172970
    [No Abstract]   [Full Text] [Related]  

  • 34. [Detection of telomerase activity in prostate needle-biopsy samples].
    Wang X; Zhang Y; Ding Q; Ye L; Zhai L; Jia W
    Zhonghua Wai Ke Za Zhi; 1999 Dec; 37(12):762-4. PubMed ID: 11829949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prostate carcinoma: higher COX-2 contents in advanced tumors].
    Weiss J; Friedrich MG
    Aktuelle Urol; 2004 Sep; 35(5):359-61. PubMed ID: 15383996
    [No Abstract]   [Full Text] [Related]  

  • 36. Arginase activity in prostatic tissue of patients with benign prostatic hyperplasia and prostatic carcinoma.
    Harris BE; Pretlow TP; Bradley EL; Whitehurst GB; Pretlow TG
    Cancer Res; 1983 Jun; 43(6):3008-12. PubMed ID: 6189588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steroid 5-alpha reductase type 2 activity in biopsies from malignant and normal prostatic tissues.
    Oliveira OL; Koff WJ; Muraro F; Santos EB; Gomes Soares DF; Trindade VM
    Clin Chim Acta; 2008 May; 391(1-2):36-40. PubMed ID: 18328817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
    Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
    J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia.
    Lee LM; Pan CC; Cheng CJ; Chi CW; Liu TY
    Anticancer Res; 2001; 21(2B):1291-4. PubMed ID: 11396201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isocitrate dehydrogenase activity in untreated and treated benign prostatic hypertrophy and adenocarcinomatous prostate.
    Leus R; van Sande M; Van Camp K
    Acta Urol Belg; 1981 Jan; 49(1):61-3. PubMed ID: 6163342
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.